PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions

[1]  L. Fournel,et al.  Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. , 2019, Cancer letters.

[2]  Steven J. M. Jones,et al.  Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma , 2019, The Journal of pathology.

[3]  S. Haferkamp,et al.  Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases , 2019, Cancer Immunology, Immunotherapy.

[4]  E. Oki,et al.  Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. , 2018, Surgical oncology.

[5]  Young Tae Kim,et al.  Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. , 2018, Gynecologic oncology.

[6]  A. Santarelli,et al.  High PD‐L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta‐analysis of the literature , 2018, Cell proliferation.

[7]  X. Xie,et al.  Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. , 2018, Cancer research.

[8]  Y. Maehara,et al.  Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. , 2018, European journal of cancer.

[9]  Xian‐Zheng Zhang,et al.  PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug. , 2018, Small.

[10]  Huyi Liang,et al.  PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer , 2018, Journal of Cancer.

[11]  I. Wistuba,et al.  Immunohistochemical and Image Analysis‐Based Study Shows That Several Immune Checkpoints are Co‐expressed in Non–Small Cell Lung Carcinoma Tumors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Z. Pan,et al.  Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer , 2018, World journal of gastroenterology.

[13]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[14]  W. Horninger,et al.  High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma , 2018, Cancer science.

[15]  M. Mino‐Kenudson,et al.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma , 2018, Endocrine Pathology.

[16]  S. Pileri,et al.  Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 , 2017, Oncotarget.

[17]  H. Baba,et al.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.

[18]  Y. Kitagawa,et al.  The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma. , 2017, Journal of pediatric surgery.

[19]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[20]  Xinlong Li,et al.  PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis , 2017, PloS one.

[21]  L. Pusztai,et al.  Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance , 2017, Breast Cancer Research.

[22]  B. Bryan,et al.  PD-1 and PD-L1 expression in bone and soft tissue sarcomas. , 2017, Pathology.

[23]  C. James,et al.  Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival , 2017, Clinical Cancer Research.

[24]  Lei Liu,et al.  Prognostic significance of PD-L1 in solid tumor , 2017, Medicine.

[25]  R. Ferris,et al.  Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients , 2017, Cancer Immunology Research.

[26]  C. Schwartz,et al.  Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease , 2017, Current Treatment Options in Oncology.

[27]  K. Shimizu,et al.  PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer , 2017, Cancer Immunology, Immunotherapy.

[28]  K. Tsuta,et al.  PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining , 2017, International Journal of Clinical Oncology.

[29]  H. Mankin,et al.  Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells , 2017, Oncotarget.

[30]  J. Miao,et al.  PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load , 2017, Scientific Reports.

[31]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[32]  F. Garrido,et al.  The absence of HLA class I expression in non‐small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration , 2017, International journal of cancer.

[33]  F. Zhou,et al.  Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma , 2017, Oncoimmunology.

[34]  C. Genestie,et al.  Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Schilham,et al.  Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[36]  M. Seto,et al.  PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. , 2016, Blood.

[37]  A. Talhouk,et al.  Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy , 2016, Clinical Cancer Research.

[38]  N. Agarwal,et al.  Immunotherapy of advanced renal cell carcinoma: Current and future therapies , 2016, Human vaccines & immunotherapeutics.

[39]  R. Herbst,et al.  Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer , 2016, Clinical Cancer Research.

[40]  X. Zang,et al.  Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma , 2016, Scientific Reports.

[41]  J. Chung,et al.  Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[42]  N. Matsumura,et al.  Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity , 2016, Clinical Cancer Research.

[43]  Mu-Kuan Chen,et al.  High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma , 2015, PloS one.

[44]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[45]  F. Gao,et al.  Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.

[46]  G. Nielsen,et al.  Programmed Cell Death Ligand 1 Expression in Osteosarcoma , 2014, Cancer Immunology Research.

[47]  N. Matsumura,et al.  PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction , 2013, Clinical Cancer Research.

[48]  Y. Iwamoto,et al.  Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J , 2009, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[49]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[50]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[51]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[52]  H. Baba,et al.  IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer , 2018 .